Reagan, A.* ; Gu, X.* ; Hauck, S.M. ; Ash, J.D.* ; Cao, G.* ; Thompson, T.C.* ; Elliott, M.H.*
Retinal caveolin-1 modulates neuroprotective signaling.
Adv. Exp. Med. Biol. 854, 411-418 (2016)
Caveolin-1 (Cav-1), the scaffolding protein of caveolae, is expressed in several retinal cell types and is associated with ocular pathologies. Cav-1 modulates neuroinflammatory/neuroprotective responses to central nervous system injury. We have shown that loss of Cav-1 results in a blunted cytokine response in retinas challenged with inflammatory stimuli. As neuroinflammatory and neuroprotective signaling overlap in their cytokine production and downstream signaling pathways, we hypothesized that loss of Cav-1 may also suppress neuroprotective signaling in the retina. To test this, we subjected mice in which Cav-1 was deleted specifically in the retina to a neurodegenerative insult induced by sodium iodate (NaIO3) and measured STAT3 activation, a measure of neuroprotective signaling. Our results show that Cav-1 ablation blunts STAT3 activation induced by NaIO3. STAT3 activation in response to intravitreal administration of the IL-6 family cytokine, leukemia inhibitory factor (LIF), was not affected by Cav-1 deletion indicating a competent gp130 receptor response. Thus, Cav-1 modulates neuroprotective signaling by regulating the endogenous production of neuroprotective factors.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Keywords
Caveolin-1 ; Cre/lox ; Conditional Knockout ; Neuroprotection ; Cytokines ; Sodium Iodate ; Stat3; Breakdown; Barrier
Keywords plus
Language
english
Publication Year
2016
Prepublished in Year
HGF-reported in Year
2015
ISSN (print) / ISBN
0065-2598
e-ISSN
ISBN
Book Volume Title
Conference Title
Retinal Degenerative Diseases : Mechanisms and Experimental Therapy
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 854,
Issue: ,
Pages: 411-418
Article Number: ,
Supplement: ,
Series
Publisher
Springer
Publishing Place
New York
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Enabling and Novel Technologies
PSP Element(s)
G-505700-001
Grants
Copyright
Erfassungsdatum
2015-10-13